Cancer Targeted Technology LLC

Pullman, WA

UEI
G2CENLL6M648
CAGE
5DHD8
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Limited Liability Company
Entity structure
Partnership or Limited Liability Partnership
SAM.gov registration date
Physical address
100 Dairy Rd #479, Pullman, WA 99163, USA
Employees
1-10
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
Development of an innovative psma-targeted radionuclide therapy for prostate cancer HHSN261201500074C National Cancer Institute (NIH) $2,300,000

Grant awards

Award Agency Obligated Awarded
Development of an innovative psma-targeted small molecule prodrug for prostate cancer R44CA290973 National Cancer Institute (NIH) $4,399,996
Development of a commercial-ready kit for CTT1403, a novel psma-targeted radiotherapy R44CA257799 National Cancer Institute (NIH) $5,000,002
Clinical evaluation of an innovative psma-targeted radiotherapy, CTT1403, in prostate cancer R44CA239461 National Cancer Institute (NIH) $3,915,089
Development of a psma-targeted small-molecule drug conjugate for prostate cancer R43CA221511 National Cancer Institute (NIH) $300,000
Clinical evaluation of a novel prostate cancer pet diagnostic R44CA192451 National Cancer Institute (NIH) $2,000,000

Latest 5 listed here. See the rest on GovTribe.

Quick answers

Is Cancer Targeted Technology LLC registered in SAM.gov?

Yes. Cancer Targeted Technology LLC's SAM.gov registration is active through June 9, 2027.

What is Cancer Targeted Technology LLC's most recent federal award?

Cancer Targeted Technology LLC's most recent federal grant award is Development of an innovative psma-targeted small molecule prodrug for prostate cancer (R44CA290973), from National Cancer Institute (NIH), on September 2, 2024.

On GovTribe

See Cancer Targeted Technology LLC's full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login